◈ Nootpedia
Compact view
Research pass: thorough Supplement · Powder OPTIONAL-ADD MEDIUM-LOW

Glycine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD MEDIUM-LOW

Sleep evidence at 3 g pre-bed is real but thin (two small Ajinomoto-funded trials, no independent replication, modest effect sizes on subjective metrics). NMDA glycine-site mechanism is well-established but generic — substrate is not rate-limiting in healthy adults. Cheap and safe enough that it's defensible as a daily-driver, but for Dylan specifically the V5 plan correctly flags it for replacement with l-tryptophan, which has stronger evidence and better mechanism-fit for late-chronotype melatonin pathway support. Verdict would shift to STRONG-CANDIDATE if (a) independent non-Ajinomoto replication of the 3 g sleep effect appeared, or (b) Dylan's bloodwork showed kynurenine-shunt reasons l-tryptophan won't work. Verdict would shift to SKIP if a credible safety signal emerged at 3 g (none currently exists).

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD

    (currently V4) / PHASING-OUT (V5). Real but thin sleep evidence; tryptophan is mechanism-superior for late-chronotype phase-advance. Verdict-confidence MEDIUM-LOW.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    Cheap, safe, mild subjective sleep benefit possible; not a primary sleep tool. Behind tryptophan, magnesium, theanine in priority. Verdict-confidence MEDIUM-LOW.

  • 50+, mild cognitive decline / longevity-framework
    OPTIONAL-ADD

    GSH-substrate angle (with cysteine via NAC) gains relevance with age; the Sekhar GlyNAC protocol has small but real evidence in older adults for oxidative stress markers and muscle/cognitive measures. 3-5 g/day reasonable, paired with cysteine. Verdict-confidence MEDIUM.

  • Anxiety-prone
    SKIP-FOR-NOW

    No human RCT support for anxiolytic effect at supplement doses; spinal/brainstem GlyR is not a primary anxiety circuit. Theanine, magnesium, taurine are better-evidenced anxiolytic adjuncts. Verdict-confidence LOW.

  • High athletic load, tested status
    OPTIONAL-ADD

    Not WADA-banned. Mild GSH-precursor angle for oxidative load; sleep angle. No direct ergogenic evidence. 3-5 g/day defensible, low priority. Verdict-confidence LOW.

  • Sleep-disordered
    OPTIONAL-ADD

    Plausible mild sleep-onset benefit at 3 g pre-bed for hot-room or thermoregulation-limited sleepers. Behind tryptophan, magnesium, melatonin, CBT-I in priority. 4-8 week trial reasonable; if no subjective improvement, drop. Verdict-confidence MEDIUM-LOW.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    GSH-substrate + collagen-substrate angles are mechanistically reasonable but not strongly evidence-backed at supplement doses. 5 g/day during acute recovery defensible. Verdict-confidence LOW-MEDIUM.

  • Strength/anabolic-focused
    SKIP-FOR-NOW

    No direct strength/anabolic evidence. Creatine substrate angle is non-load-bearing because direct creatine supplementation is cheaper and more efficient. Collagen-for-joints angle is weak. Verdict-confidence LOW.

▸ Subjective experience (deep)

Per user reports:

  • Onset: 30-60 min after dose. The most common subjective is mild warmth or relaxation, not sedation.
  • Peak: 60-120 min. Faster sleep onset reported by responders; some report no effect at all.
  • Sleep: Subjectively easier sleep onset in maybe 30-50% of responders; effect is subtle — not the "knockout" feel of antihistamines or Z-drugs. No grogginess at 3 g doses.
  • Dreams: Mild vivid-dream effect in some users; less than l-tryptophan.
  • Morning: No grogginess. Some users report feeling more rested on glycine nights, others report no difference.
  • Daytime use (rare protocol): A few biohackers take 1-3 g daytime as a "subtle calm" — mostly no effect or very mild relaxation; not a useful daytime tool.

Variability is high. Many users (especially those with already-good sleep) report no perceptible effect. Responders skew toward those with mild sleep-onset issues + warm bedrooms. This pattern is consistent with the thermoregulation mechanism — if your core body temperature is already dropping cleanly at bedtime, adding more vasodilation does little.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: None established. Glycine is substrate-level supplementation, not receptor-pushing.
  • Recommended cycle: None needed. Daily-safe indefinitely.
  • Reset protocol: N/A.
  • If subjective effect dims over weeks → suspect placebo washout, change in bedroom temperature/environment, or unrelated sleep variable. Not a glycine tolerance effect.
▸ Stacking deep dive

Synergistic with

  • magnesium-glycinate — Dylan already takes 400 mg elemental Mg as glycinate (V4). The glycinate form contributes a small additional glycine load (~1-2 g equivalent depending on exact salt formulation), but the bulk supplemental glycine and the "glycinate" carrier are not pharmacologically distinct in terms of CNS delivery — calling them "synergistic" is mostly a marketing frame. They're additive substrate, both safe pre-bed.
  • l-tryptophan — different mechanism (substrate vs thermoregulation); could co-administer pre-bed without antagonism. Not recommended for Dylan because of pill burden + the V5 plan is the parsimony-driven swap, not stack. A maximalist pre-bed sleep stack would include both.
  • l-theanine (V4: 200 mg) — different mechanism (GABA/glutamate), additive subjective relaxation. Fine to co-administer.
  • n-acetyl-cysteine (V4: 1200 mg) — provides cysteine; combined with glycine improves glutathione synthesis substrate base. The "GlyNAC" Sekhar protocol uses ~100 mg/kg glycine + ~100 mg/kg NAC for older-adult GSH restoration; for a healthy 20-year-old the GSH-substrate angle is far less load-bearing than in age-related decline. Defensible incidental co-administration; not a primary indication.
  • magnesium (any form) — Mg is a calming pre-bed adjunct via NMDA modulation + GABA-A facilitation; glycine + Mg is a common pre-bed pair. Already in V4 via Mg-glycinate + magtein.
  • apigenin (V5 plan) — different mechanism (GABA-A PAM). Additive sedation likely mild; safe stack.
  • collagen peptides — collagen is glycine-rich; if user is taking collagen for joints/skin, additional glycine supplementation has diminishing returns.

Replaces (in V5 plan)

  • L-Tryptophan — explicit V5 swap. See Dylan-specific dosing above.

Avoid stacking with

  • Strychnine — joke. Strychnine is a glycine receptor antagonist; not a real-world concern.
  • No clinically meaningful contraindications at supplement doses. Glycine is one of the safest amino acid supplements.

Neutral / safe co-administration

  • All V4 stack components.
  • All V5 planned additions: modafinil, bromantane, Adamax/Semax, ALCAR, apigenin, astaxanthin, l-tryptophan, taurine.
  • Caffeine, creatine, beta-alanine.
  • All Rx medications Dylan is not on but might consider — no documented interactions.
▸ Drug interactions deep dive

Glycine is one of the lowest-interaction supplements in the pharmacopeia.

Drug class Concern level Notes
Clozapine LOW-MODERATE Some early schizophrenia adjunct work suggested glycine may blunt clozapine response in negative-symptom patients (the so-called "clozapine paradox"). Not relevant to Dylan.
Antihypertensives LOW Theoretical additive vasodilation; no clinical reports at 3 g.
Antipsychotics (general) LOW Adjunct use intentional in schizophrenia trials; no negative interaction signal in healthy users on antipsychotics for off-label reasons.
CYP enzymes None Glycine is not a CYP substrate or inhibitor. No CYP-mediated interactions.
Contraceptives None No interaction.
All other Rx classes None reported Glycine is endogenous and dietary — pharmacological interaction profile is essentially blank.

This minimal interaction profile is one of glycine's strongest features and the reason it's a defensible "low-risk experimental" supplement even when evidence is thin.

▸ Pharmacogenomics

Limited PGx data of practical significance for supplement-dose glycine:

  • GLDC (glycine decarboxylase / glycine cleavage system T-protein) variants — loss-of-function mutations cause nonketotic hyperglycinemia (severe neonatal encephalopathy). Heterozygous carriers may have mildly elevated baseline plasma glycine. No actionable supplementation guidance.
  • GlyT1 / SLC6A9 (glycine transporter) variants — affect synaptic glycine reuptake. Linked to schizophrenia susceptibility in some studies. Sarcosine (the GlyT1 inhibitor) targets this transporter pharmacologically. Variants don't currently translate to actionable glycine-dose recommendations.
  • GlyR (GLRA1, GLRB) subunit variants — cause hyperekplexia (exaggerated startle disorder). Pharmacogenomically relevant to strychnine sensitivity / glycine-receptor modulators, not to oral glycine dose.
  • Methylation pathway variants (MTHFR, MTHFD1, etc.) — glycine is consumed in one-carbon metabolism (glycine ↔ serine via SHMT, glycine ↔ CO₂ via the glycine cleavage system, donating one-carbon units). MTHFR variants affecting one-carbon flux could theoretically alter glycine demand, but the supplemental dose dwarfs metabolic demand and no actionable PGx-glycine interaction is established.
  • 23andMe relevance for Dylan (June 2026 results): Worth noting baseline plasma glycine if amino acid panel is ordered, but no actionable change to 3 g dose is expected based on current PGx evidence. File for context.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC NOW Foods Glycine 1000 mg caps ~$8-10/mo at 3 g/day HIGH Dylan's current V4 source via iHerb. Reliable, cheap.
OTC bulk BulkSupplements glycine powder ~$15-20 / 1 kg (~10-11 mo at 3 g/day) HIGH Cheapest per gram; powder mixes easily, mildly sweet. Best long-term cost.
OTC Nootropics Depot glycine powder ~$10-15 / 250-500 g HIGH Third-party tested, CoA available.
OTC Doctor's Best, Source Naturals, Jarrow ~$8-15/mo HIGH All reputable.
OTC Amazon generics ~$5-10/mo MEDIUM Brand variability; check CoA when available.
OTC Pharmaceutical IV-grade (research only) — HIGH Used in IV nutrition; not a supplement path.

Recommended for Dylan (if continuing — not recommended for V5): Stay with NOW Foods 1000 mg caps via iHerb (current vendor flow). If V5 swap is implemented, drop entirely; no glycine purchase in next iHerb cycle.

V5 swap math: Drop NOW Foods Glycine 3 caps/day ($8-10/mo) → add NOW Foods L-Tryptophan 2 caps/day ($13-15/mo). Net: +$3-5/mo. Negligible. Pill count drops 3 → 2. Evidence quality improves materially.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • Subjective sleep diary — sleep onset latency, WASO, total sleep time, morning grogginess (1-10 scale) for 7-14 days. The single most actionable measure for Dylan since labs come in June.
  • Plasma amino acid panel (specialty / not standard CMP) — includes glycine, serine, optional. Useful for baseline; not actionable for routine dosing.
  • Glutathione (GSH/GSSG ratio) — specialty assay; relevant only if oxidative stress is the indication.
  • Bedroom temperature log — important confound for the thermoregulation mechanism.

During use

  • Sleep diary metrics weekly for first month, monthly after.
  • Subjective sleep quality (1-10) weekly.
  • If response is null at 4 weeks: drop the trial and reassess. No deeper biomarker work justified for healthy adults.

Post-cycle (if ever cycled)

  • N/A — no cycling needed.

Trial framework for Dylan's V5 swap (recommended)

Run as A/B test:

  1. Continue current glycine 3 g pre-bed; track sleep diary for 14 days (baseline).
  2. Switch to l-tryptophan 1 g pre-bed; track sleep diary for 14-28 days.
  3. Compare subjective sleep onset latency, WASO, morning grogginess.
  4. Decision rule: if tryptophan ≥ glycine on net, finalize swap. If tryptophan < glycine on net, swap back or trial both stacked.
▸ Controversies / open debates Live debate

1. Are the Ajinomoto-funded sleep trials trustworthy?

This is the central evidence-quality question. Both major glycine sleep trials (Yamadera 2007, Bannai 2012) are authored by Ajinomoto researchers and funded by Ajinomoto — the world's largest amino acid manufacturer with direct commercial interest in establishing glycine as a sleep supplement.

Steel-man for the trials:

  • Methodology was reasonable for early-stage industry-sponsored work (PSG used in Bannai 2012, multiple subjective scales, placebo control, crossover design).
  • Effect sizes are modest, not implausibly large — consistent with small-but-real biological effect.
  • Mechanism (thermoregulation via core temp drop) is independently confirmed in animal models and is biologically coherent.
  • No outright fraud allegations; Ajinomoto is a legitimate research-publishing company.

Reasons for skepticism:

  • No independent (non-Ajinomoto) replication has been published in 14+ years. This is the killer concern. If the effect were robust, an independent group would have replicated it given the cheap, safe nature of the intervention.
  • Small n (10-19 per trial), short duration (2-3 nights), subjective endpoints in Yamadera, sleep-restriction model in Bannai (which may inflate apparent effect vs healthy unrestricted sleep).
  • The effect size on PSG-measured sleep onset latency in Bannai 2012 was reported but the absolute magnitude is modest (single-digit minutes shorter).
  • Industry-sponsored amino acid trials with minimal independent replication are a pattern in nutrition science.

Best read: the effect is likely real but small, and the dose-response relationship and population responder profile are under-characterized. Calling glycine "F-grade evidence" (per Dylan's earlier V3 framing) is somewhat harsh — there are at least PSG-level data points — but calling it A-tier or strong-evidence overstates what the literature supports. MEDIUM-LOW confidence is the honest read.

2. NMDA glycine site — relevant for healthy cognition or schizophrenia-only?

The NMDA glycine-site mechanism is real and well-characterized, but the site is approximately saturated under normal physiological conditions in healthy adults. Supplementing additional glycine substrate doesn't push the system because synaptic glycine + D-serine are sufficient. Sarcosine (GlyT1 inhibitor) raises synaptic glycine more efficiently than oral glycine, and even sarcosine's cognitive effects in healthy adults are modest at best. Healthy biohackers expecting glycine to be a "cognitive enhancer" via NMDA modulation are largely misled. The schizophrenia trial dose range (10-60 g/day) is what's required for measurable NMDA-site effect, and even there benefit is modest and inconsistent.

3. Is the "glycine for sleep" mechanism really thermoregulatory or really NMDA?

Bannai 2012 framed the mechanism as thermoregulation via NMDA-modulated suprachiasmatic nucleus → autonomic peripheral vasodilation. This is the best-supported mechanism, and it's coherent with why glycine works better in warmer environments and in mild-insomniacs (whose thermoregulation is presumably less efficient). Some authors propose direct glycine receptor effects in sleep-relevant brainstem nuclei, but GlyT1-mediated CNS uptake limits the magnitude of any direct receptor effect from oral dosing. The thermoregulation framing is the cleanest current model.

4. Glycine vs L-tryptophan vs both — what's the right pre-bed amino acid?

For Dylan: tryptophan wins on evidence + mechanism-fit, glycine is the legacy V4 choice. For other profiles (hot-room sleepers, kynurenine-shunt high-CRP individuals where tryptophan is blunted, those who specifically respond to thermoregulation interventions), glycine retains a niche. Both are mutually compatible — no antagonism. The V5 swap is parsimony-driven; a maximalist sleep stack could include both. Magnesium glycinate is a non-trivial supplemental glycine source (V4 has 400 mg elemental Mg as glycinate, contributing ~1-2 g equivalent glycine load), which further reduces the case for adding standalone glycine on top in V5.

5. Is glycine a "GSH/longevity" supplement?

The Sekhar GlyNAC literature in older adults is real but small (n=8, n=24 in different trials) and specifically requires combined glycine + cysteine — glycine alone is insufficient. Dylan already has NAC 1200 mg in V4 (cysteine source) + 3 g glycine in V4 (current), so the GlyNAC substrate base is partially covered. For a 20-year-old, the GSH-substrate-limitation premise (which is age-related) is much weaker than for a 60-year-old. Net: glycine's "longevity" framing is an extrapolation from older-adult data to a population (young athletes) where it likely does much less.

6. The V3 "F-grade" verdict — was it too harsh?

Dylan's earlier V3 framing called glycine F-grade, citing the Ajinomoto-sponsored trials and lack of replication. This characterization was directionally right but somewhat overstated. The trials are real, methodology was reasonable, mechanism is biologically coherent, and the safety profile is essentially perfect. MEDIUM-LOW confidence is more accurate than F-grade. That said, the V5 swap to l-tryptophan is the right call regardless of how harshly glycine is graded — tryptophan is simply a better fit for Dylan's specific profile.

▸ Verdict change log
  • 2026-05-06 — Initial verdict: OPTIONAL-ADD (currently V4) / PHASING-OUT (V5) with MEDIUM-LOW confidence. Sleep evidence is two small Ajinomoto-funded trials with no independent replication; mechanism (thermoregulation via core body temperature drop) is biologically coherent; safety is essentially perfect; cognitive enhancement claims at typical doses are not evidence-backed; NMDA glycine-site mechanism is real but generic and likely non-rate-limiting in healthy adults. For Dylan specifically: V5 plan correctly swaps glycine 3 g for l-tryptophan 1 g pre-bed because tryptophan has stronger evidence (A-tier vs B-tier industry-funded), better mechanism-fit for late-chronotype melatonin pathway, and trivial net cost increase (+$3-5/mo). Verdict would shift to STRONG-CANDIDATE only if independent non-Ajinomoto replication of the 3 g sleep effect appeared, or if Dylan's June 2026 bloodwork showed kynurenine-shunt reasons l-tryptophan won't work (high hs-CRP, unaddressed inflammation). Verdict would shift to SKIP only if a credible safety signal emerged at 3 g (none currently exists; safety profile is one of the cleanest in the pharmacopeia).
▸ Open questions / gaps Open
  1. Will an independent group ever replicate the Ajinomoto sleep trials? Cheap, safe, mechanistically interesting — the absence of replication after 14+ years is itself informative.
  2. Is the responder profile thermoregulation-driven (hot bedroom, peripheral vasoconstriction baseline)? The mechanism predicts this but it's never been directly tested.
  3. Does the V4 magnesium glycinate (400 mg elemental, ~1-2 g equivalent glycine load) functionally substitute for standalone glycine supplementation? No direct comparison data. Plausible that it does, in which case adding 3 g standalone is partial duplication.
  4. A/B test outcome for Dylan's V5 swap: does subjective sleep diary actually improve on tryptophan vs glycine over 4-8 weeks? The single most informative open question. Will resolve via in-progress trial.
  5. Is the GlyNAC longevity protocol applicable to 20-year-olds? No direct trial data; theoretically weaker rationale than in older adults.
  6. Sarcosine vs glycine for NMDA-site effect — sarcosine raises synaptic glycine more efficiently. For users specifically targeting the NMDA glycine site (schizophrenia adjunct, theoretical cognitive effect), sarcosine is mechanistically the right tool. Not relevant to Dylan but worth filing.
▸ Sources (full, with our context)
Back to compact view